DnB Markets - Morgenrapport 26. mai: Ikke fullt så motstandsdyktig likevel

Report

DnB Markets

FICC Analyst FICC Analyst

Morgenrapport 26. mai: Ikke fullt så motstandsdyktig likevel

Morgenrapport 26. mai: Ikke fullt så motstandsdyktig likevel (2 pages)

26/05/2023 1 EN

Provider

DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

See profile

Analysts

FICC Analyst FICC Analyst

Other Reports from DnB Markets

Rune Majlund Dahl

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK1040.00) - Disappointing CagriSema data

In REDEFINE-1, CagriSema reached a 22.7% product estimand weight loss, shy of expectations. We expect a launch in 2026, but have lowered our estimate of its sales potential. In our view, the flexible protocol affected efficacy, prompting Novo Nordisk to initiate a new phase III trial in 2025. We reiterate our BUY, but have cut our target price to DKK1,040 (1,150).

Free Trial

17h / 21m 17h / 21m 1 EN

Alexander Aukner

Alexander Aukner

SalMar (Buy, TP: NOK690.00) - Below consensus for Q4e

Our below-consensus trend continues, having adjusted Q4e for a lower spot price. We estimate operating EBIT of NOK1,276m, ~22% below consensus of NOK1,627m. While we have reduced our price forecasts, we have raised the superior share and the margin in VAP and Sales. We reiterate our BUY and NOK690 target price. The Q4 results are due at 06:30 CET on 18 February.

Free Trial

22h / 56m 22h / 56m 1 EN

Alexander Aukner

Alexander Aukner

Seafood - Fat Trout Weekly

Free Trial

23h / 59m 23h / 59m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morgenrapport 26. mai: Ikke fullt så motstandsdyktig likevel

Novo Nordisk (Buy, TP: DKK1040.00) - Disappointing CagriSema data

SalMar (Buy, TP: NOK690.00) - Below consensus for Q4e

Seafood - Fat Trout Weekly

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe